DrugPatentWatch Database Preview
Details for Patent: 10,016,435
» See Plans and Pricing
Which drugs does patent 10,016,435 protect, and when does it expire?
Patent 10,016,435 protects IMBRUVICA and is included in two NDAs.
This patent has forty-one patent family members in seventeen countries.
Summary for Patent: 10,016,435
| Title: | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
| Abstract: | Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile. |
| Inventor(s): | Buggy; Joseph J. (Mountain View, CA), Elias; Laurence (Berkeley, CA), Fyfe; Gwen (San Francisco, CA), Hedrick; Eric (Summit, NJ), Loury; David J. (Incline Village, NV), Mody; Tarak D. (Sunnyvale, CA) |
| Assignee: | Pharmacyclics LLC (Sunnyvale, CA) |
| Application Number: | 15/715,995 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 10,016,435 |
|
Patent Claim Types: see list of patent claims | Use; Dosage form; |
Drugs Protected by US Patent 10,016,435
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmacyclics Inc | IMBRUVICA | ibrutinib | CAPSULE;ORAL | 205552-002 | Dec 20, 2017 | RX | Yes | No | Start Trial | Start Trial | TREATMENT OF WALDENSTROM'S MACROGLOBULINEMIA | Start Trial | ||||
| Pharmacyclics Inc | IMBRUVICA | ibrutinib | CAPSULE;ORAL | 205552-001 | Nov 13, 2013 | RX | Yes | Yes | Start Trial | Start Trial | TREATMENT OF WALDENSTROM'S MACROGLOBULINEMIA | Start Trial | ||||
| Pharmacyclics Inc | IMBRUVICA | ibrutinib | TABLET;ORAL | 210563-001 | Feb 16, 2018 | RX | Yes | No | Start Trial | Start Trial | TREATMENT OF WALDENSTROM'S MACROGLOBULINEMIA | Start Trial | ||||
| Pharmacyclics Inc | IMBRUVICA | ibrutinib | TABLET;ORAL | 210563-002 | Feb 16, 2018 | RX | Yes | No | Start Trial | Start Trial | TREATMENT OF WALDENSTROM'S MACROGLOBULINEMIA | Start Trial | ||||
| Pharmacyclics Inc | IMBRUVICA | ibrutinib | TABLET;ORAL | 210563-003 | Feb 16, 2018 | RX | Yes | No | Start Trial | Start Trial | TREATMENT OF WALDENSTROM'S MACROGLOBULINEMIA | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,016,435
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2011261185 | Start Trial | |||
| Australia | 2015275321 | Start Trial | |||
| Australia | 2018204179 | Start Trial | |||
| Australia | 2020202752 | Start Trial | |||
| Brazil | 112012030625 | Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
